Toh Norihisa, Ishii Katsuhisa, Kihara Hajime, Iwakura Katsuomi, Watanabe Hiroyuki, Yoshikawa Junichi, Ito Hiroshi
Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences.
Circ J. 2016;80(2):426-34. doi: 10.1253/circj.CJ-15-0815. Epub 2015 Dec 25.
Hypertension increases the risk of left ventricular (LV) diastolic dysfunction, and anti-hypertensive therapy may improve LV relaxation. The aim of this study was to investigate whether combining an angiotensin-receptor blocker (ARB) with either hydrochlorothiazide (HCTZ) or a calcium-channel blocker (CCB) improves LV relaxation in patients with hypertension and diastolic dysfunction.
Hypertensive patients who had not achieved their target blood pressure with at least 4 weeks of ARB therapy were randomly assigned to receive either a fixed-dose combination of losartan and HCTZ (losartan/HCTZ; n=110) or a combination of amlodipine and a typical ARB dosage (CCB/ARB; n=121) and followed for 24 weeks. The primary endpoint was change in early diastolic mitral annular velocity (e', cm/s). Systolic blood pressure decreased in both groups after switch to the combination therapies. E' velocity increased both in the losartan/HCTZ (0.52 cm/s) and in the CCB/ARB (0.59 cm/s) groups. The mean (95% CI) treatment difference was -0.02 (-0.37 to 0.34) cm/s, indicating that improvement in LV relaxation was similar between the groups. The ratio of early mitral inflow velocity to e' velocity and left atrial volume index were significantly decreased in the losartan/HCTZ group.
The combination of losartan and HCTZ is as effective as amlodipine plus ARB in improving LV relaxation in hypertensive patients.
高血压会增加左心室(LV)舒张功能障碍的风险,而抗高血压治疗可能会改善左心室舒张功能。本研究的目的是探讨血管紧张素受体阻滞剂(ARB)与氢氯噻嗪(HCTZ)或钙通道阻滞剂(CCB)联合使用是否能改善高血压合并舒张功能障碍患者的左心室舒张功能。
接受至少4周ARB治疗但未达到目标血压的高血压患者被随机分配接受氯沙坦与HCTZ的固定剂量组合(氯沙坦/HCTZ;n = 110)或氨氯地平和典型ARB剂量的组合(CCB/ARB;n = 121),并随访24周。主要终点是舒张早期二尖瓣环速度(e',cm/s)的变化。两组在改用联合治疗后收缩压均下降。氯沙坦/HCTZ组(0.52 cm/s)和CCB/ARB组(0.59 cm/s)的e'速度均增加。平均(95% CI)治疗差异为-0.02(-0.37至0.34)cm/s,表明两组之间左心室舒张功能的改善相似。氯沙坦/HCTZ组早期二尖瓣流入速度与e'速度之比以及左心房容积指数显著降低。
氯沙坦与HCTZ联合使用在改善高血压患者左心室舒张功能方面与氨氯地平加ARB同样有效。